Dorado Medical Complex
Dorado 00646
3 studies enrolling now · 12 studies all time
What they study most
Cardiovascular Diseases, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Diabetes Type 2, Hypertension, Obesity, Osteoarthritis, Overweight, Overweight or Obesity, Type 2 Diabetes
Studies at this site
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — Recruiting now
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Recruiting now
- A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) — Running, not enrolling
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 — Running, not enrolling
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 — Running, not enrolling
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) — Completed
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
- A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes — Running, not enrolling
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities — Running, not enrolling
- A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus — Completed